Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Akisü M et al. | The effect of L-carnitine on platelet activating factor concentration in the immature rat model of hypoxic-ischemic brain injury. | 1998 | Acta Med. Okayama | pmid:9781268 |
Hashimoto K et al. | Comparison of the effects of intra-third ventricular administration of interleukin-1 or platelet activating factor on ACTH secretion and the sympathetic-adrenomedullary system in conscious rats. | 1993 | Acta Med. Okayama | pmid:8384777 |
Vargaftig BB et al. | One, two, three or more pathways for platelet aggregation. | 1980 | Acta Med. Scand. Suppl. | pmid:6779505 |
Hirasima Y et al. | Platelet-activating factor (PAF) and the development of chronic subdural haematoma. | 1994 | Acta Neurochir (Wien) | pmid:7998491 |
Hirashima Y et al. | Platelet-activating factor (PAF) and the formation of chronic subdural haematoma. Measurement of plasma PAF levels and anti-PAF immunoglobulin titers. | 1995 | Acta Neurochir (Wien) | pmid:8748861 |
Hirashima Y et al. | Platelet-activating factor and antiphospholipid antibodies in subarachnoid haemorrhage. | 1994 | Acta Neurochir (Wien) | pmid:7847132 |
Hallenbeck JM | Blood-damaged tissue interaction in experimental brain ischemia. | 1994 | Acta Neurochir Suppl (Wien) | pmid:7976554 |
Tokutomi T et al. | Effect of platelet-activating factor antagonist on brain injury in rats. | 1994 | Acta Neurochir Suppl (Wien) | pmid:7976632 |
Maeda T et al. | Hemodynamic depression and microthrombosis in the peripheral areas of cortical contusion in the rat: role of platelet activating factor. | 1997 | Acta Neurochir. Suppl. | pmid:9416292 |
Khan SN et al. | Response to platelet-activating factor of platelets from patients with multiple sclerosis. | 1985 | Acta Neurol. Scand. | pmid:3993327 |
Satoh K et al. | Increased levels of blood platelet-activating factor (PAF) and PAF-like lipids in patients with ischemic stroke. | 1992 | Acta Neurol. Scand. | pmid:1574985 |
Doly M et al. | Protective effect of a specific PAF antagonist on vincristine-induced experimental retinopathy. | 1995 | Acta Ophthalmol Scand | pmid:7656145 |
Pettorossi VE and Grassi S | Different contributions of platelet-activating factor and nitric oxide in long-term potentiation of the rat medial vestibular nuclei. | 2001 | Acta Otolaryngol Suppl | pmid:11677732 |
Nakano T et al. | Roxythromycin reinforces epithelial defence function in rabbit trachea. | 1998 | Acta Otolaryngol Suppl | pmid:9879427 |
Minami T et al. | Regional blood flow volume in the eustachian tube. | 1993 | Acta Otolaryngol Suppl | pmid:8452027 |
Lin J et al. | Effects of platelet-activating factor (PAF) receptor blockage on mucous glycoprotein secretion in cultured chinchilla middle ear epithelium. | 1996 | Acta Otolaryngol. | pmid:8820353 |
Terada N et al. | The effect of anti-VLA-4 monoclonal antibody on eosinophil accumulation and leukotriene production in nasal mucosa. | 1996 | Acta Otolaryngol. | pmid:8973726 |
Ganbo T and Hisamatsu K | Mucosal dysfunction and damage induced by platelet activating factor (PAF). | 1990 Nov-Dec | Acta Otolaryngol. | pmid:2284918 |
Dolata J et al. | The influence of leukotrienes and platelet activating factor on mucociliary activity in the rabbit maxillary sinus. | 1990 Jan-Feb | Acta Otolaryngol. | pmid:2309553 |
Furukawa M et al. | Presence of platelet-activating factor in nasal polyps and eosinophils. | 2002 | Acta Otolaryngol. | pmid:12542208 |